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Skeletal Muscle Fibre-Specific
Knockout of p53 Does Not Reduce
Mitochondrial Content or Enzyme
Activity
Ben Stocks 1, Jessica R. Dent 1, Sophie Joanisse 1, Carrie E. McCurdy 2 and Andrew Philp 1*
1 School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom,
2Department of Human Physiology, University of Oregon, Eugene, OR, United States
Tumour protein 53 (p53) has been implicated in the regulation of mitochondrial biogenesis
in skeletal muscle, with whole-body p53 knockout mice displaying impairments in basal
mitochondrial content, respiratory capacity, and enzyme activity. This study aimed to
determine the effect of skeletal muscle-specific loss of p53 on mitochondrial content
and enzyme activity. Mitochondrial protein content, enzyme activity and mRNA profiles
were assessed in skeletal muscle of 8-week-old male muscle fibre-specific p53 knockout
mice (p53 mKO) and floxed littermate controls (WT) under basal conditions. p53 mKO
and WT mice displayed similar content of electron transport chain proteins I-V and
citrate synthase enzyme activity in skeletal muscle. In addition, the content of proteins
regulating mitochondrial morphology (MFN2, mitofillin, OPA1, DRP1, FIS1), fatty acid
metabolism (β-HAD, ACADM, ACADL, ACADVL), carbohydrate metabolism (HKII, PDH),
energy sensing (AMPKα2, AMPKβ2), and gene transcription (NRF1, PGC-1α, and TFAM)
were comparable in p53 mKO and WT mice (p > 0.05). Furthermore, p53 mKO mice
exhibited normal mRNA profiles of targeted mitochondrial, metabolic and transcriptional
proteins (p > 0.05). Thus, it appears that p53 expression in skeletal muscle fibres is
not required to develop or maintain mitochondrial protein content or enzyme function in
skeletal muscle under basal conditions.
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INTRODUCTION
Tumour protein p53 (p53) was initially characterised as a tumour suppressor protein (Matoba
et al., 2006; Vousden and Prives, 2009; Muller and Vousden, 2013), serving to regulate cellular
metabolism and proliferation (Zhou et al., 2003; Bensaad et al., 2006; Matoba et al., 2006). More
recently, a functional role of p53 for in vivo skeletal muscle physiology has been proposed, following
observations that p53 can regulate apoptosis (Saleem et al., 2009), atrophy (Fox et al., 2014),
autophagy (Saleem et al., 2014), mitochondrial DNA stability (Saleem andHood, 2013; Safdar et al.,
2016), post-exercise signalling (Saleem et al., 2009, 2014), mitochondrial function (Park et al., 2009;
Saleem et al., 2009, 2014; Wang et al., 2013) and endurance performance (Park et al., 2009; Saleem
et al., 2009; Wang et al., 2013) within skeletal muscle.
Whole-body knockout (KO) of p53 in mice results in a deficient skeletal muscle mitochondrial
phenotype (Park et al., 2009; Saleem et al., 2009), displaying reduced mitochondrial mass, mtDNA
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copy number, cytochrome-c oxidase enzyme activity, and
state 3 respiration (Park et al., 2009; Saleem et al., 2009).
As a consequence, endurance capacity and voluntary wheel
running are also reduced in p53 KO mice (Park et al., 2009;
Saleem et al., 2009). In comparison, oncogenic p53 mutations
found in the Li-Fraumeni syndrome increase in vivo skeletal
muscle oxidative phosphorylation in humans (Wang et al.,
2013), while mitochondrial respiration and content of electron
transport chain proteins is increased in primary myoblasts
from Li-Fraumeni carriers and in mice carrying a p53 R712H
polymorphism (Wang et al., 2013). Thus, it is clear that p53 plays
an important role in mitochondrial metabolism and function.
Whilst loss of p53 impairs mitochondrial function,
importantly, p53 KO mice still respond to endurance exercise
training (Saleem et al., 2009). Specifically, p53 KO and WT mice
display similar increases in cytochrome-c oxidase activity with
training, while trained p53 KO mice exhibit no difference in
electron micrograph determined subsarcolemmal mitochondrial
density compared to trained WT mice (Saleem et al., 2009). This
suggests that p53 is not essential for endurance exercise induced
mitochondrial adaptations (Saleem et al., 2009; Safdar et al.,
2016), and the functional deficits of p53 KO appear to arise in
the basal (i.e., non-exercised) state.
Despite the wealth of evidence that p53 is important for
whole-body metabolism and skeletal muscle mitochondrial
function, determining the importance of p53 specifically in
skeletal muscle cannot be ascertained from models of whole-
body p53 deletion. In such models, it cannot be excluded that
phenotypic differences in skeletal muscle physiology may arise as
secondary defects due to dysfunction induced by the loss of p53
in other cell types. Thus, to elucidate the role of p53 specifically
within skeletal muscle fibres, this study determined the effect of
skeletal muscle fibre-specific loss of p53 (mKO) onmitochondrial
content and enzyme activity in skeletal muscle.
MATERIALS AND METHODS
Mouse Strains
The development and validation of the p53mKOmouse has been
described previously (Fox et al., 2014). Briefly, p53 mKO mice
were generated by crossing homozygous p53 floxed mice (p53f/f;
exons 2–10 of the p53 gene are flanked by LoxP restriction sites)
with mice expressing cre recombinase (Cre) under the control
Abbreviations: ACADM, Acyl-CoA dehydrogenase medium chain; ACADL,
Acyl-CoA dehydrogenase long chain; ACADVL, Acyl-CoA dehydrogenase very
long chain; AMPK, 5′ AMP-activated protein kinase alpha; ATP5A, ATP synthase
subunit alpha; β-HAD, 3-hydroxyacyl-CoA dehydrogenase; Cre, Cre recombinase;
CS, Citrate synthase; Cyt-c, Cytochrome-c; DRP1, Dynamin-1-like protein;
eEF2, Eukaryotic elongation factor 2; FIS1, Mitochondrial fission protein 1;
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; HKII, Hexokinase II; KO,
Knockout; MCK, Muscle creatine kinase; MFN2, Mitofusin 2; mKO, Muscle
fibre-specific knockout; MTCO1, Cytochrome c oxidase subunit I; NDUFB8,
NADH:Ubiquinone Oxidoreductase Subunit B8; NRF1, Nuclear respiratory factor
1; OPA1, Dynamin-like 120 kDa protein; PDH, Pyruvate dehydrogenase; PGC-
1α, Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; P53,
Tumour protein p53; SDHB, Succinate Dehydrogenase Complex Iron Sulphur
Subunit B; TFAM, Mitochondrial transcription factor A; UQCRC2, Ubiquinol-
Cytochrome C Reductase Core Protein II.
of the muscle creatine kinase (MCK) promoter. Control mice
(WT) were p53f/f littermates that lack the MCK-Cre transgene.
All mice were on a C57BL/6 background. Eight-week old male
mice were used for all experiments. Mice were housed in colony
cages at 21◦Cwith 12:12-h light-dark cycles and ad libitum access
to standard laboratory chow (Harlan-Teklad formula 7913) and
water. All animal procedures were approved by the Institutional
Animal Care and Use Committee of the University of Iowa.
Tissue Collection and Preparation
Muscle was obtained from young (8-weeks old), healthy mice
under basal conditions. Gastrocnemius, quadriceps and triceps
muscle was rapidly dissected and rinsed to remove blood and
fur before being snap-frozen in liquid nitrogen. Muscle was
powdered using a Cellcrusher tissue pulverizer (Cellcrusher, Co.
Cork, Ireland) on dry ice and stored at−80◦C prior to analysis.
Immunoblotting
Tissue was homogenised in a 10-fold mass excess of ice-cold
sucrose lysis buffer (50mM Tris, 1mM EDTA, 1mM EGTA,
50mM NaF, 5mM Na4P2O7-10H2O, 270mM sucrose, 1M
Triton-X, 25mM β-glycerophosphate, 1µM Trichostatin A,
10mM Nicatinamide, 1mM 1,4-Dithiothreitol, 1% Phosphatase
Inhibitor Cocktail 2; Sigma, 1% Sigma Phosphatase Inhibitor
Cocktail 2; Sigma, 4.8% cOmplete Mini Protease Inhibitor
Cocktail; Roche) by shaking in a FastPrep 24 5G (MP
Biomedicals, Santa Ana, California, USA) at 6.0 m·s−1
for 80 s and centrifuging at 4◦C and 8,000 g for 10min
to remove insoluble material. Protein concentrations were
determined by the DC protein assay (Bio-Rad, Hercules,
California, USA). Samples were boiled at 97◦C for 5min
in laemmli sample buffer and an equal volume of protein
(20–50 µg) was separated by SDS-PAGE on 8–12.5% gels
at a constant current of 23mA per gel. To demonstrate the
loss of p53 in mKO skeletal muscle (Figure 1B), the triceps
muscle from mKO and WT mice were immunoblotted.
Gastrocnemius, quadriceps and triceps muscle were all
immunoblotted to examine the effect of p53 mKO on the
content of mitochondrial (Figures 2, 3), metabolic (Figure 4)
and signalling and transcriptional (Figure 5) proteins. The
presented data is from gastrocnemius muscle. Proteins were
transferred on to BioTrace NT nitrocellulose membranes (Pall
Life Sciences, Pensacola, Florida, USA) via wet transfer at
100V for 1 h. Membranes were then stained with Ponceau
S (Sigma-Aldrich, Gillingham, UK) and imaged to check for
even loading. Membranes were blocked in 3% dry-milk in
tris-buffered saline with tween (TBST) for 1 h before being
incubated in primary antibody overnight at 4◦C. Membranes
were washed in TBST three times prior to incubation in
appropriate horse radish peroxidase-conjugated secondary
antibody at room temperature for 1 h. Membranes were then
washed in TBST three times prior to antibody detection via
enhanced chemiluminescence horseradish peroxidase substrate
detection kit (Millipore, Watford, UK). Imaging and band
quantification were undertaken using a G:Box Chemi-XR5
(Syngene, Cambridge, UK).
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FIGURE 1 | Confirmation of p53 deletion in p53 mKO mouse model. (A) Reduction in Trp53 mRNA expression in quadriceps muscle of p53 mKO (grey squares) vs.
WT (black circles) mice (n = 3–4 per group). (B) Reduction in p53 protein content in triceps muscle of p53 mKO mice (n = 4 per group). *p ≤ 0.05 mKO vs. WT; **p ≤
0.01 mKO vs. WT. (C) Representative immunofluorescence images for WT (left column) and mKO (right column) tibialis anterior muscle. The top row represents p53
only (red), the middle row shows a composite image of p53 (red), dystrophin (green), and dapi (blue), the third row shows an enlarged image of regions highlighted
with a white box in the middle row. A reduction in overall staining can be seen in mKO compared to WT. Positive regions of p53 outside of the myofibre are apparent in
both WT and mKO muscle and have been highlighted in dotted boxes in the third row. Myonuclei positive for p53 are apparent only in WT muscle and have been
highlighted in yellow ovals in the third row. The scaling line in each image represents 50µM.
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FIGURE 2 | Mitochondrial OXPHOS protein content and CS enzyme activity in p53 mKO (grey squares) and WT (black circles) mice. (A) WT and p53 mKO mice
display similar protein content of mitochondrial enzymes (complexes I-V, CS, and Cyt-c) in gastrocnemius muscle (p > 0.05; n = 6 per group). Similar data is apparent
in triceps and quadriceps muscle (data not shown). (B) Similar CS enzyme activity in triceps muscle of p53 mKO and WT mice (p > 0.05; n = 6–7 per group). Similar
data is apparent in gastrocnemius and quadriceps muscle (data not shown). (C) Representative immunoblot images.
Antibodies
All primary antibodies were used at a concentration of 1:1000
in TBST unless otherwise stated. Antibodies: 3-hydroxyacyl-
CoA dehydrogenase (β-HAD; 37673), Mitofillin (110329)
and MitoProfile OXPHOS antibody cocktail (110413) from
abcam; cytochrome-c (Cyt-c; 556433) from BDPharmingen;
5′ AMP-activated protein kinase alpha (AMPKα; 2603),
AMPKβ2 (4148), dynamin-1-like protein (DRP1; 8570),
glyceraldehyde 3-phosphate dehydrogenase (GAPDH;
2118; 1:5000), eukaryotic elongation factor 2 (eEF2; 2332),
hexokinase II (HKII; 2867), mitofusin 2 (MFN2; 9482), pyruvate
dehydrogenase (PDH; 2784) and p53 (2524; 1:1000 in 5%
non-fat dry milk in TBST) from Cell Signaling Technologies;
Dynamin-like 120 kDa protein (OPA1; CPA3687) from
Cohesion Biosciences; peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC-1α; ST1202)
from EMD Millipore; citrate synthase (CS; SAB2701077),
mitochondrial fission protein 1 (FIS1; HPA017430; 1:500), and
mitochondrial transcription factor A (TFAM; SAB1401383)
from Sigma-Aldrich; Acyl-CoA dehydrogenase medium chain
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FIGURE 3 | Proteins controlling mitochondrial morphology are unchanged in p53 mKO (grey squares) compared to WT (black circles) mice. (A) WT and p53 mKO
mice display similar content of proteins regulating mitochondrial fusion (MFN2, mitofillin, OPA1) and fission (DRP1 and FIS1) in gastrocnemius muscle (p > 0.05; n = 6
per group). Similar data is apparent in triceps and quadriceps muscle (data not shown). (B) Representative immunoblot images.
FIGURE 4 | Abundance of fat and carbohydrate metabolism proteins are consistent between p53 mKO (grey squares) and WT (black circles) mice. (A) WT and p53
mKO mice display similar protein content of proteins involved in fatty acid (ACADM, ACADL, ACADVL, and β-HAD) and carbohydrate (HKII and PDH) metabolism in
gastrocnemius muscle (p > 0.05; n = 6 per group). Similar data is apparent in triceps and quadriceps muscle (data not shown). (B) Similar β-HAD enzyme activity in
triceps muscle of p53 mKO and WT mice (p > 0.05; n = 6–7 per group). Similar data is apparent in gastrocnemius and quadriceps muscle (data not shown).
(C) Representative immunoblot images.
(ACADM; 1:2000), Acyl-CoA dehydrogenase long chain
(ACADL; 1:5000), Acyl-CoA dehydrogenase very long chain
(ACADVL; 1:5000) were kind gifts from Prof Jerry Vockley,
University of Pittsburgh, USA. Secondary antibodies were used
at a concentration of 1:10000 in TBST. Anti-rabbit (7074)
and anti-mouse (7076) antibodies were from Cell Signaling
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FIGURE 5 | Protein content of mitochondrial biogenic signalling and transcriptional proteins in p53 mKO (grey squares) and WT (black circles) mice. (A) The content of
proteins regulating energy sensing (AMPKα, AMPKβ2), nuclear transcription (NRF1 and PGC-1α) and mitochondrial transcription (TFAM) are comparable in
gastrocnemius muscle of WT (black circles) and p53 mKO (grey squares) mice (p > 0.05; n = 6 per group). Similar results were observed in triceps and quadriceps
muscle (data not shown). (B) The mRNA expression of Pparg1a and Tfam are similar in quadriceps muscle of WT (black circles) and p53 mKO (grey squares) mice
(p > 0.05; n = 4 per group). (C) Representative immunoblot images.
Technology; anti-chicken (PA1-28798) was from Thermo
Scientific.
Immunofluorescence
Tibialis anterior skeletal muscle was embedded and frozen in
tissue freezing medium (Triangle Biomedical, Durham, North
Carolina, USA) in nitrogen-cooled isopentane, muscle samples
were stored at −80◦C. Skeletal muscle cross sections (7µM)
of WT and mKO tibialis anterior muscle were prepared using
a microtome blade (Bright 5040, Bright Instrument Company
limited, Huntingdon, England).Muscle sections ofWT andmKO
were collected onto the same uncoated glass slides and stored at
−80◦C until future analysis. Samples were thawed and fixed in an
acetone:methanol (1:1) solution at −20◦C then washed in PBS.
Samples were permeabilised in a 0.2% TritonX-100 solution for
10min, then washed in PBS and followed by a 30min incubation
in 5% normal goat serum (Invitrogen, UK) prepared in 1% BSA.
Samples were then incubated in p53 primary antibody (SCBT
sc-6243, rabbit, polyclonal; 1:20) prepared in 1% BSA overnight
at 4◦C. Slides were washed in PBS and incubated for 2 h in
goat anti rabbit IgG Alexa 594 (ThermoFisher Scientific Inc.
Waltham, MA, USA; 1:200) secondary antibody. Slides were then
stained for dystrophin (DSHB, MANDYS1, mouse, monoclonal;
1:200) for 2 h, washed in PBS and treated with goat anti mouse
IgG2a Alexa 488 (ThermoFisher Scientific Inc. Waltham, MA,
USA 1:200) secondary antibody for 2 h. Nuclei were labelled with
DAPI (4′,6-diamidino-2-phenylindole) (1:1000, Sigma-Aldrich,
UK), prior to cover slipping with 20 µL Mowiol R© 4-88 (Sigma-
Aldrich, UK). Appropriate secondary antibody only control
slides were used to ensure the specificity of the p53 antibody
and that no apparent staining of dystrophin was visualized using
the 540–580 nm excitation filter in which p53 was detected.
Slides were visualised using a Nikon E600 widefield microscope
with a 40 × 0.75 numerical aperture objective. Images were
captured under three colour filters using a SPOT RT KE colour
three shot CCD camera (Diagnostic Instruments Inc., MI, USA),
illuminated by a 170W Xenon light source. All images were
captured using the same exposure time and gain for p53 staining
in both WT and mKOmuscle sections.
Citrate Synthase and 3-Hydroxyacyl-coA
Dehydrogenase Enzyme Activity Assays
Tissue was homogenised in a 10-fold mass excess of ice-cold
sucrose muscle homogenisation buffer (Spinazzi et al., 2012) by
shaking in a FastPrep 24 5G (MP Biomedicals) at 6.0 m.s−1 for
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80 s. Protein concentrations were determined by the DC protein
assay (Bio-Rad, Hercules, California, USA). Gastrocnemius,
quadriceps, and triceps muscle were all analysed for enzyme
activity with data presented from triceps muscle. An equal
volume of protein (10 µg for CS, 20 µg for β-HAD) was loaded
onto 96-well microtiter plates in triplicate. For CS, 10 µL of
sample was diluted in 235 µL of reaction buffer [64mM TRIS
pH 8.0, 0.13mM 5,5-dithio-bis-(2-nitrobenzoic acid), 0.13mM
acetyl CoA]. Five microlitres of 5mM oxaloacetate was added to
start the reaction and absorbance was read at 412 nm for 3min in
a FLUOstar Omega microplate reader (BMG Labtech, Aylesbury,
UK). For β-HAD, 15 µL of sample was diluted in 230 µL of
reaction buffer (68mM TRIS pH 8.0, 270mM NADH, 270mM
EDTA, 270mM Triton X-100). Five mictolitres of 5mM aceto-
acetyl CoA was added to start the reaction and absorbance was
read at 340 nm for 12min. Enzyme activity in nmol.min−1.mg−1
was determined from absorbance using the equation presented in
Spinazzi et al. (2012) corrected for differences in pathlength.
RNA Isolation and Reverse
Transcription—Polymerase Chain Reaction
RNA was extracted from quadriceps muscle by Tri reagent
(Sigma Aldrich, Gillingham, UK) and purified on Reliaprep
spin columns (Promega, Madison, Wisconsin, USA) using
the manufacturer’s instructions. RNA concentrations were
determined using the LVis function of the FLUOstar Omega
microplate reader. RNA was diluted to 400 µg/µL and reverse
transcribed to cDNA using the RT2 First Strand kit (Qiagen,
Manchester, UK). RT-PCR analysis of mRNA content was
performed in singleton by using custom designed 384-well RT2
PCR Profiler Array (Qiagen) and RT2 SYBR Green Mastermix
(Qiagen) on a CFX384 Real-Time PCR Detection System (Bio-
Rad). 2.8 ng of cDNA was added to each well. The absence of
genomic DNA, the efficiency of reverse-transcription and the
efficiency of the PCR assay were assessed on each plate and
conformed to the manufacturers limits in each case. Relative
mRNA expression was determined using the 2−11CT method
(Livak and Schmittgen, 2001) with the mean CT value for Gapdh,
Actb, Hsp90ab1, and B2m used as an internal control.
Statistics
Difference between genotypes was determined by independent
t-tests using the Statistical Package for the Social Sciences (SPSS)
version 22.0. Data is presented as means with 95% confidence
intervals. Statistical significance was accepted as p ≤ 0.05.
RESULTS
Confirmation of p53 Deletion in the p53
mKO Mouse Model
In agreement with the previous characterisation of the p53 mKO
model (Fox et al., 2014) we observed an ∼70% reduction in
Trp53 mRNA (Figure 1A), while an ∼60% reduction in p53
protein content (Figure 1B) in skeletal muscle tissue from p53
mKO mice was also apparent. Immunofluorescence staining of
WT and mKO tibialis anterior muscle cross sections indicates
an overall reduction in p53 staining and a loss of p53-positive
myonuclei (Figure 1C). However, non-myofibrillar p53 staining
is apparent in both WT and mKO muscle suggesting that the
remaining p53 apparent in immunoblots of mKO muscle likely
reflects expression from non-muscle fibre cells resident within
skeletal muscle tissue.
Mitochondrial Content and Enzyme Activity
Is Maintained in p53 mKO
Despite deletion of p53 in skeletal muscle fibres, the content of
proteins within the electron transport chain were similar between
p53 mKO and WT littermates (Figure 2A). Maximal activity of
citrate synthase (Figure 2B), a strong correlate and validated
surrogate of mitochondrial content (Larsen et al., 2012), as well as
cytochrome-c and citrate synthase protein content (Figure 2A)
were also maintained in p53 mKO mice. In addition, proteins
involved in the regulation of mitochondrial fission (DRP1, Fis1)
and fusion (MFN2, mitofillin, OPA1) were also unaffected by
p53 mKO (Figure 3). Thus, mitochondrial protein content and
enzyme activity in skeletal muscle is maintained followingmuscle
fibre-specific deletion of p53.
Loss of p53 Does Not Alter Regulators of
Substrate Metabolism in Skeletal Muscle
p53 mKO did not reduce the content of proteins involved in fatty
acid transport and metabolism (ACADM, ACADl, ACADVL,
β-HAD) or carbohydrate metabolism (HKII, PDH; Figure 4A).
Furthermore, the activity of the mitochondrial-localised fatty
acid metabolic protein β-HAD was unaffected by p53 mKO
(Figure 4B).
Proteins Controlling Energy Sensing and
Mitochondrial Gene Expression Are
Unaffected by p53 mKO
Whole-body p53 KOmice exhibit reduced skeletal musclemRNA
and protein expression of TFAM (Park et al., 2009) and protein
content of PGC-1α (Saleem et al., 2009), while p53 has been
implicated in the transcriptional control of AMPK subunits
(Feng et al., 2007). Therefore, we studied the protein content of
PGC-1α, TFAM, AMPKα, AMPKβ2, or NRF1 within p53 mKO
skeletal muscle. In contrast to whole-body p53 KO mice, p53
mKO does not reduce the protein content of PGC-1α, TFAM,
AMPKα, AMPKβ2, or NRF1 within skeletal muscle (Figure 5A)
or the mRNA expression of PGC-1α or TFAM (Figure 5B).
Gene Expression of Proteins Involved in
Skeletal Muscle Function and Metabolism
p53 mKO did not affect the mRNA expression of a sub-
set of electron transport chain, mitochondrial morphology,
mitochondrial transport, carbohydrate and fatty acid
metabolism, transcription, angiogenic, or muscle development
genes (Figure 6).
DISCUSSION
We report that muscle-specific deletion of p53 does not reduce
mitochondrial protein content or enzyme activity within skeletal
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FIGURE 6 | p53 mKO and WT mice display similar mRNA expression of (A) electron transport chain proteins and proteins involved in regulating (B) mitochondrial
morphology, (C) mitochondrial protein transport, (D) muscle development, (E) carbohydrate and fatty acid metabolism, (F) transcription and (G) angiogenesis. Each
column represents the mRNA expression from the quadriceps muscle of a single mouse (p > 0.05; n = 4 per group).
muscle. This is in contrast to previous research from whole-body
p53 KO mice which reported a reduction in mitochondrial mass,
mtDNA copy number, cytochrome-c oxidase enzyme activity,
and state 3 respiration (Park et al., 2009; Saleem et al., 2009).
Given these discrepancies, we therefore interpret the data to
suggest that the decrement in skeletal muscle mitochondrial
function in whole-body p53 KOmice is a secondary consequence
of an adverse phenotype of this mouse model, rather than due the
loss of p53 per se in skeletal muscle fibres.
p53 has been implicated in metabolic control within
numerous cell types (Zhou et al., 2003; Bensaad et al., 2006;
Matoba et al., 2006). Indeed, p53 can exert direct or indirect
transcriptional control over variousmetabolic andmitochondrial
biogenic proteins in some cell types [e.g., PGC-1α (Saleem
et al., 2009), TFAM (Park et al., 2009; Saleem et al., 2009),
CO1 (Okamura et al., 1999), SCO2 (Matoba et al., 2006),
AMPKβ (Feng et al., 2007), TIGAR (Bensaad et al., 2006), and
GLUT4 (Schwartzenberg-Bar-Yoseph et al., 2004)]. However, our
data suggests that in skeletal muscle, p53 is not required to
maintain mitochondrial content and function. For example, the
maximal activities of citrate synthase and the protein content
of electron transport chain proteins were maintained in p53
mKO mice. In addition, the content of proteins controlling
mitochondrial morphology, substrate utilisation, energy sensing,
and transcription were comparable between p53 mKO and WT
mice. The muscles examined within this study were, however,
all predominantly made up of fast-fibre types and it cannot
be excluded that a different phenotype may be apparent in
predominantly slow-fibre type muscles. Nonetheless, this data
does suggest a normal metabolic phenotype of p53 mKO mice
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under basal conditions and is consistent with a similar skeletal
muscle fibre-type distribution and diameter previously reported
in p53 mKOmice (Fox et al., 2014).
Unimpaired mitochondrial biogenesis in skeletal muscle of
p53 mKO mice is in contrast to data published from whole-
body p53 KO mice (Saleem et al., 2009). Why whole-body p53
KO mice exhibit mitochondrial defects within skeletal muscle
while p53 mKO mice do not is unclear. One explanation for
the divergent phenotypes may be differences in the timing
of p53 deletion in skeletal muscle between the two models.
In the mKO mice examined here Cre was expressed under
the MCK promoter and as such p53 would not be deleted
until ∼13 days into embryonic development (Lyons et al.,
1991), whereas p53 is absent throughout the entirety of
embryonic development in the germline deletion of the whole-
body KO mice. Importantly, p53 is highly expressed in mouse
embryos from embryonic day 8.5–10.5 (Schmid et al., 1991).
During myogenesis, p53 plays an important role in inducing
differentiation (Porrello et al., 2000; Cam et al., 2006); a period
of intense mitochondrial biogenesis (Remels et al., 2010). p53−/−
myoblasts and C2C12 myoblasts treated with dominant-negative
p53 inhibitors display impaired myosin heavy chain induction
during differentiation, potentially due to reduced expression of
the muscle differentiation controlling proteins retinoblastoma
protein (RB) and MCK (Porrello et al., 2000; Cam et al.,
2006). Although direct evidence for a lack of mitochondrial
development during differentiation in p53−/− myoblasts is
lacking, mitochondrial deficits may arise in the whole-body KO
mice due to a lack of p53 during this developmental period,
while conversely p53 is expressed in skeletal muscle of the
embryonic p53 mKO mice during this stage. Additionally, a loss
of p53 in satellite cells in whole-body KO mice may impair
satellite cell differentiation into myocytes (Porrello et al., 2000)
during adulthood and therefore the continued regeneration and
maintenance of healthy skeletal muscle (Relaix and Zammit,
2012). Thus, the loss of p53 in one or multiple cell type(s)
other than muscle fibres may contribute to a decrement in
mitochondrial function within skeletal muscle.
Several differences are also apparent in the expression of
mitochondrial biogenic transcription factors/co-factors between
the whole-body KO and mKO models. Park et al. (2009)
demonstrated that p53 interacts with the TFAM gene in C2C12
myoblasts and that TFAM expression is reduced in the soleus
muscle of whole-body p53 KO mice. Furthermore, PGC-1α
protein content was decreased in p53 KO mice examined
by Saleem et al. (2009), although this contradicts similar
PGC-1α protein content found between WT and p53 KO
mice by Park et al. (2009). In the p53 mKO mice studied
here there was no deficit in TFAM or PGC-1α protein or
mRNA expression, which may explain the normal mitochondrial
phenotype exhibited by p53 mKO mice. Alternatively, given
the developmental nature of the mKO model, other regulators
of mitochondrial biogenesis (Perez-Schindler and Philp, 2015)
may be compensating for the loss of p53 in skeletal muscle,
however exploration of all these pathways is outside the scope of
this investigation. Thus, an inducible muscle-specific knockout
model is still required to determine whether p53 is important
for maintaining mitochondrial function in mature skeletal
muscle.
Finally, the whole-body p53 KO mouse may not be a healthy
model. Whole-body p53 KO mice exhibit reduced voluntary
wheel running (Saleem et al., 2009), which if recapitulated
as lower spontaneous physical activity in non-exercised mice
may explain the reduced mitochondrial function. Furthermore,
whole-body p53 KO mice develop spontaneous cancers at an
early age (Donehower et al., 1992), something that is often
concomitant with cachexia and impaired muscle function.
Nonetheless, utilising a muscle fibre-specific knockout model
allows us, and others (Safdar et al., 2016), to assess p53 function
within skeletal muscle without the complications of potential
secondary defects associated with loss of p53 in other cell types.
While p53 within skeletal muscle fibres does not appear
critical for developing or maintaining mitochondrial content
within skeletal muscle of young healthy mice in the basal
state, p53 does clearly play a role within skeletal muscle in
other physiological contexts. For example, induction of p53
contributes to immobilisation-induced atrophy by orchestrating
transcription of Cdkn1a/p21 and possibly other genes that
promote muscle fibre atrophy, whereas p53 mKO mice are
protected from atrophy (Fox et al., 2014). p53 is also important in
maintaining mitochondrial DNA stability and mediates exercise-
induced mitochondrial biogenesis in PolG KO mice, a model of
accelerated mitochondrial mutations (Safdar et al., 2016). Thus,
it is likely that the importance of p53 may become apparent
during ageing. Furthermore, it remains to be determined whether
p53 mKO mice respond to endurance exercise training although
whole-body p53 KO mice are uninhibited in this respect (Saleem
et al., 2009), which would indicate that p53 mKO would also be
responsive to endurance exercise training.
Our data suggests that muscle fibre-specific deletion of p53
does not impair mitochondrial protein content or enzyme
activity in skeletal muscle. This is evidenced by similar content
of proteins within the electron transport chain and proteins
regulating mitochondrial morphology, substrate utilisation,
energy sensing, and transcription between WT and p53 mKO
mice. In addition, there were no deficits in the activity of the
mitochondrial enzymes CS and β-HAD in p53 mKOmice. While
p53 likely has other roles in skeletal muscle physiology, from this
data it does not appear that skeletal muscle p53 is important
for developing or maintaining mitochondrial content in young
healthy mice.
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